NovaBay Pharmaceuticals NBY 深 沪
已收盘 08-22 16:00:00 美东时间
0.9101
-0.160
-14.94%
华盛通- 最 高1.10
- 今 开1.01
- 成交量 169.64万股
- 最 低 0.9101
- 昨 收 1.07
- 总市值 529.33万
- 52周最高 1.25
- 市盈率 静 --
- 换手率 29.17%
- 52周最低 0.44
- 委 比 33.33%
- 总股本 581.62万
- 历史最高 62168.75
- 量 比 0.04
- 振 幅 17.75%
- 历史最低 0.46
- 每 手 1
- 风险率 0.08%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多3 Penny Stocks to Watch Now, 8/21/25
Tharimmune, NovaBay Pharmaceuticals, and Auddia are the 3Penny Stocks&nbs...
08-21 19:13
NovaBay Stock Is Trading Higher Wednesday: What's Going On?
NovaBay Pharmaceuticals, Inc. (AMEX:NBY) stock is trading higher on Wednesday a...
08-21 03:33
Why Is NovaBay Pharmaceuticals Stock (NBY) Up 60% Today?
NovaBay Pharmaceuticals stock rallied on Wednesday alongside a $6 million deal ...
08-20 19:58
NovaBay Pharmaceuticals Entered Into A $6M Securities Purchase Agreement With Private Investor David E. Lazar For The Purchase Of The Company's Non-Voting Convertible Preferred Stock; Effective Immediately, Mr. Lazar Has Been Appointed NovaBay's Chief Executive Officer And A Director Of The Company
EMERYVILLE, Calif., Aug. 19, 2025 (GLOBE NEWSWIRE) -- NovaBay® Pharmaceuticals, Inc. (NYSE:NBY) ("NovaBay" or the "Company") announces it has entered into a $6 million securities purchase agreement with private
08-20 05:31
NovaBay Pharmaceuticals Enters Into $6 Million Securities Purchase Agreement with Investor David E. Lazar
NovaBay Pharmaceuticals has entered into a $6 million securities purchase agreement with private investor David E. Lazar, receiving the first closing of $3.85 million. Lazar has been appointed CEO, while former CEO Justin Hall becomes Vice President of Business Development. The transaction prevents NovaBay’s liquidation and allows its shares to continue trading. Proceeds will fund strategic investments or acquisitions, and a special cash dividend...
08-19 21:25
NovaBay Pharmaceuticals Q2 EPS $(0.34) Misses $(0.21) Estimate
NovaBay Pharmaceuticals (AMEX:NBY) reported quarterly losses of $(0.34) per share which missed the analyst consensus estimate of $(0.21) by 61.9 percent. This is a 75.18 percent increase over losses of $(1.37) per share
08-15 04:50
又一个刚入华的时尚品牌盯上了中女们的钱包
文｜贺哲馨 编辑｜乔芊 除了户外赛道，还有能力开店的时尚品牌不多了，Phoebe Philo算一个。 最近，Phoebe Philo在中国连签下五个零售商，除了...
08-06 08:27
Shares of several biotechnology stocks are trading higher amid Vinay Prasad's departure as director of the FDA's Center for Biologics Evaluation and Research.
Shares of several biotechnology stocks are trading higher amid Vinay Prasad's d...
07-31 02:12
Ascendiant Capital Maintains Buy on NovaBay Pharmaceuticals, Adjusts Price Target To $0.85 (1-35 Reverse Stock Split)
Ascendiant Capital analyst Edward Woo maintains NovaBay Pharmaceuticals (AMEX:NBY) with a Buy, adjusts target to $0.85 from $8 (1-35 Reverse Stock Split).
2024-11-12 01:44
NovaBay accepts higher PRN offer, says Refresh deal no longer superior
NovaBay (NYSE:NBY) said it has accepted a revised offer from PRN Physician Recommended Nutriceuticals that increases the base purchase price of its Avenova eyecare business to $11.5M from $9.5M. In ad...
2024-11-07 05:49
